Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
VCAM-1/CD106 Antibody (B-K9), Alexa Fluor™ 350, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP247864AF350
Description
VCAM-1/CD106 Monoclonal specifically detects VCAM-1/CD106 in Human, Rat samples. It is validated for Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunofluorescence.Specifications
VCAM-1/CD106 | |
Monoclonal | |
Alexa Fluor 350 | |
50 mM sodium borate with 0.05% sodium azide | |
VCAM1 | |
Activated human umbilical vein endothelial cells (HUVEC) | |
0.1 mL | |
Primary | |
Recognizes a protein of 110kDa, identified as CD106 (also known as vascular cell adhesion molecule-1 (VCAM-1) and INCAM-100). CD106 is a member of the Ig superfamily of adhesion molecules and is expressed at high levels on cytokine stimulated vascular endothelial cells, and at minimal levels on un-stimulated endothelial cells. It is also present on follicular and inter-follicular dendritic cells of lymph nodes, myoblasts, and some macrophages. CD106 serves as a ligand for leukocyte integrin (VLA-4 or CD49d/CD29) and mediates cell adhesion of leukocytes to activated endothelium. It plays a role in various immunological and inflammatory responses. This monoclonal antibody inhibits the binding of leukocytes to VCAM-1 on stimulated endothelial cells. | |
Store at 4°C in the dark. |
Flow Cytometry, Immunofluorescence | |
B-K9 | |
Flow Cytometry, Immunofluorescence | |
CD106, CD106 antigen, DKFZp779G2333, INCAM-100, L1CAM, MGC99561, vascular cell adhesion molecule 1, vascular cell adhesion protein 1, V-CAM 1, VCAM1, VCAM-1 | |
Mouse | |
Protein A or G purified | |
Cancer, Mesenchymal Stem Cell Markers, Phospho Specific, Stem Cell Markers | |
7412.0 | |
Human, Rat | |
IgG1 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction